PetMeds® Announces First Quarter Financial Results
Rhea-AI Summary
PetMed Express (NASDAQ: PETS) reported first quarter 2026 net sales of $41.0 million, down 19.9% from $51.2 million a year earlier, mainly reflecting lower prescription medication sales despite reduced consumer promotions. Gross profit was $11.3 million versus $14.4 million in the prior-year period.
Net loss narrowed to $6.1 million, or $(0.28) per diluted share, from $34.2 million, or $(1.65) per share, primarily due to the absence of prior-year impairment charges and lower G&A and advertising expenses. Adjusted EBITDA was $(3.4) million compared with $(2.7) million. Operating expenses fell sharply, including a nearly 14% decline in general and administrative costs and lower advertising spend. Cash and equivalents declined to $13.1 million from $21.4 million at March 31, 2026, with $7.7 million used in operating activities. The company highlighted completion of an enterprise-wide SAP ERP rollout and a recently announced sale-leaseback aimed at strengthening its balance sheet.
Positive
- Net loss reduced to $6.1 million from $34.2 million year-over-year
- GAAP EPS improved to $(0.28) from $(1.65) year-over-year
- General and administrative expenses cut to $11.2 million from $12.9 million (~14%)
- Advertising expense reduced to $4.2 million from $6.0 million
- Net cash used in operations improved to $7.7 million from $12.3 million
- Completed enterprise-wide rollout of new SAP ERP system
Negative
- Net sales declined 19.9% year-over-year to $41.0 million
- Gross profit fell to $11.3 million from $14.4 million year-over-year
- Adjusted EBITDA loss widened to $(3.4) million from $(2.7) million
- Cash and cash equivalents decreased to $13.1 million from $21.4 million since March 31, 2026
- Net cash used in operating activities was $7.7 million in the quarter
News Explained
PetMed Express has reported results for the quarter ended
Market reaction after First quarter earnings report: PETS -8.87%
Following this news, PETS has declined 8.87%, reflecting a notable negative market reaction. Our momentum scanner has triggered 5 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $1.85. Trading volume is very high at 4.2x the average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 02 | FY26 earnings results | Negative | -16.4% | Annual sales decline, large goodwill impairment, and continued adjusted EBITDA losses |
| May 27 | FY25 earnings call | Neutral | +0.3% | Scheduled fiscal-year results release and conference call without operating results |
| Feb 10 | Q3 FY25 earnings | Positive | -14.0% | Higher sales, gross margin, adjusted EBITDA, and lower general expenses |
| Jan 30 | Q3 FY25 earnings call | Neutral | -5.2% | Scheduled quarterly results release and conference call without operating results |
| Nov 06 | Q2 FY25 earnings | Positive | +35.8% | Higher profit, gross margin, and adjusted EBITDA compared with prior year |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings reactions were mixed: positive results produced both a 35.78% alignment and a -14.04% divergence, while the latest negative earnings event aligned with a -16.43% reaction.
Key Terms
adjusted ebitda financial
sale-leaseback financial
enterprise-wide rollout technical
goodwill impairment financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
DELRAY BEACH, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its first quarter ended June 30, 2026.
Quarterly Highlights
- Net sales demonstrated sequential quarterly stabilization. For the first quarter ended June 30, 2026, net sales were
$41.0 million compared to$51.2 million for the prior year period, a decrease of19.9% , as lower consumer promotional usage was more than offset by a decline in prescription medication sales. - Net loss for the quarter ended June 30, 2026, was
$6.1 million , or$(0.28) per diluted share, compared to a net loss of$34.2 million , or$(1.65) per diluted share, for the prior year period. The decrease in net loss was primarily driven by the absence of the prior-year goodwill and trade name impairment charges and to a lesser extent lower general and administrative expenses and advertising expenses. These favorable factors were partially offset by lower gross profit primarily driven by lower manufacturer rebates as a percentage of sales, partially offset by lower net freight costs per order. - Adjusted EBITDA1 was
$(3.4) million compared to$(2.7) million in the prior year period.
“Our first quarter results reflect continued progress toward our goal of establishing a direct, clear path back to sustainable profitability,” said Leslie Campbell, Chairman and Interim CEO and President of PetMeds. “We are pleased that net sales have stabilized sequentially over the past several quarters, and we continued to make our marketing spend more efficient, acquiring 70,000 new customers while reducing our cost of acquiring a new customer by
Earnings Webcast
A webcast reviewing financial results for the first quarter fiscal year ended June 30, 2026 is available at the “News & Events” section of the Company’s investor relations website at https://investors.petmeds.com/News--Events/events-and-presentations/default.aspx.
About PetMed Express, Inc.
Founded in 1996, PetMeds is a pioneer in the direct-to-consumer pet healthcare sector. As a trusted national online pharmacy, PetMeds is licensed across all 50 states and staffed with expert pharmacists dedicated to supporting pet wellness, pets and pet parents, and the veterinarians who serve them. Through its PETS family of brands and through its PetCareRx subsidiary, the Company offers a comprehensive range of pet health solutions – including top-brand and generic pharmaceuticals, compounded medications, and better-for-your-pet OTC supplements and nutrition. Focused on value, convenience, and care, PetMeds and PetCareRx empower pet parents to help their dogs, cats, and horses live longer, healthier lives. To learn more, visit www.PetMeds.com and www.PetCareRx.com.
Forward Looking Statement
This press release may contain “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties, including the Company’s ability to meet the objectives included in its business plan. Important factors that could cause results to differ materially from those indicated by such forward-looking statements are set forth in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections in the Company’s Annual Report on Form 10-K to be filed for the year ended March 31, 2026. The Company’s future results may also be impacted by other risk factors listed from time to time in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, the Company’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and periodic filings on Form 8-K. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements, other than as may be required by law. If the Company does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements.
Investor Contact:
ICR, LLC
Reed Anderson
(646) 277-1260
investor@petmeds.com
| PETMED EXPRESS, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (In thousands, except for share and per share amounts) (Unaudited) | ||||||||
| June 30, 2026 | March 31, 2026 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 13,079 | $ | 21,412 | ||||
| Accounts receivable, less allowance for credit losses of | 1,706 | 1,908 | ||||||
| Inventories, net | 8,468 | 13,608 | ||||||
| Prepaid expenses and other current assets | 4,256 | 6,378 | ||||||
| Prepaid income taxes | 96 | 258 | ||||||
| Total current assets | 27,605 | 43,564 | ||||||
| Noncurrent assets: | ||||||||
| Property and equipment, net | 25,213 | 26,326 | ||||||
| Intangible and other assets, net | 10,549 | 10,789 | ||||||
| Operating lease right-of-use assets, net | 395 | 512 | ||||||
| Total noncurrent assets | 36,157 | 37,627 | ||||||
| Total assets | $ | 63,762 | $ | 81,191 | ||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 12,298 | $ | 20,906 | ||||
| Sales tax payable | 20,603 | 22,261 | ||||||
| Accrued expenses and other current liabilities | 6,654 | 7,665 | ||||||
| Current operating lease liabilities | 414 | 493 | ||||||
| Deferred revenue | 629 | 689 | ||||||
| Income taxes payable | — | 20 | ||||||
| Total current liabilities | 40,598 | 52,034 | ||||||
| Deferred tax liabilities, net | 175 | 175 | ||||||
| Operating lease liabilities, net of current lease liabilities | — | 42 | ||||||
| Total liabilities | $ | 40,773 | $ | 52,251 | ||||
| Shareholders’ equity: | ||||||||
| Preferred stock, | ||||||||
| Convertible preferred stock, | 9 | 9 | ||||||
| Series A Junior Participating Preferred Stock, | — | — | ||||||
| Common stock, $.001 par value, 40,000,000 shares authorized; 21,682,381 and 21,385,638 shares issued and outstanding, respectively | 22 | 21 | ||||||
| Additional paid-in capital | 19,840 | 19,647 | ||||||
| Retained earnings | 3,118 | 9,263 | ||||||
| Total shareholders’ equity | 22,989 | 28,940 | ||||||
| Total liabilities and shareholders’ equity | $ | 63,762 | $ | 81,191 | ||||
| PETMED EXPRESS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF (LOSS) INCOME (In thousands, except for share and per share amounts) (Unaudited) | ||||||||
| Three Months Ended June 30, | ||||||||
| 2026 | 2025 | |||||||
| Net sales | $ | 41,015 | $ | 51,180 | ||||
| Cost of sales | 29,682 | 36,777 | ||||||
| Gross profit | 11,333 | 14,403 | ||||||
| Operating expenses: | ||||||||
| General and administrative | 11,197 | 12,948 | ||||||
| Advertising | 4,220 | 6,046 | ||||||
| Depreciation and amortization | 2,148 | 2,283 | ||||||
| Impairment of goodwill and intangible assets | — | 27,258 | ||||||
| Total operating expenses | 17,565 | 48,535 | ||||||
| Loss from operations | (6,232 | ) | (34,132 | ) | ||||
| Other income: | ||||||||
| Interest (expense) income, net | (338 | ) | (198 | ) | ||||
| Other, net | 438 | 187 | ||||||
| Total other income (expense) | 100 | (11 | ) | |||||
| Loss before provision for income taxes | (6,132 | ) | (34,143 | ) | ||||
| Provision for income taxes | 13 | 9 | ||||||
| Net loss | $ | (6,145 | ) | $ | (34,152 | ) | ||
| Basic and diluted net loss per share | $ | (0.28 | ) | $ | (1.65 | ) | ||
| Basic and diluted weighted-average common shares outstanding | 21,682,381 | 20,755,416 | ||||||
| PETMED EXPRESS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited) | ||||||||
| Three Months Ended June 30, | ||||||||
| 2026 | 2025 | |||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | (6,145 | ) | $ | (34,152 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | 2,148 | 2,283 | ||||||
| Impairment of goodwill and intangible assets | — | 27,258 | ||||||
| Share based compensation | 198 | 591 | ||||||
| Bad debt (recovery) expense | — | (6 | ) | |||||
| (Increase) decrease in operating assets and increase (decrease) in operating liabilities: | ||||||||
| Accounts receivable | 202 | 718 | ||||||
| Inventories | 5,140 | (2,156 | ) | |||||
| Prepaid income taxes | 162 | — | ||||||
| Prepaid expenses and other current assets | 2,122 | (1,170 | ) | |||||
| Operating lease right-of-use assets, net | 117 | 112 | ||||||
| Accounts payable | (8,608 | ) | (3,523 | ) | ||||
| Sales tax payable | (1,658 | ) | 127 | |||||
| Accrued expenses and other current liabilities | (1,164 | ) | (1,287 | ) | ||||
| Lease liabilities | (121 | ) | (113 | ) | ||||
| Deferred revenue | (60 | ) | (977 | ) | ||||
| Income taxes payable | (20 | ) | 24 | |||||
| Net cash used in operating activities | (7,687 | ) | (12,271 | ) | ||||
| Cash flows from investing activities: | ||||||||
| Purchases of property and equipment | (641 | ) | (1,292 | ) | ||||
| Net cash used in investing activities | (641 | ) | (1,292 | ) | ||||
| Cash flows from financing activities: | ||||||||
| Dividends paid | — | (1 | ) | |||||
| Cash paid for tax withholding on net settlement of restricted stock | (5 | ) | (29 | ) | ||||
| Net cash used in financing activities | (5 | ) | (30 | ) | ||||
| Net decrease in cash and cash equivalents | (8,333 | ) | (13,593 | ) | ||||
| Cash and cash equivalents, at beginning of period | 21,412 | 54,720 | ||||||
| Cash and cash equivalents, at end of period | $ | 13,079 | $ | 41,127 | ||||
| Supplemental disclosure of cash flow information: | ||||||||
| Cash paid for income taxes net of refunds | $ | (120 | ) | $ | (4 | ) | ||
| Dividends payable in accrued expenses and other current liabilities | $ | — | $ | 23 | ||||
| Non-cash investing activity for property and equipment additions | $ | 155 | $ | 478 | ||||
Non-GAAP Financial Measures
To provide investors and the market with additional information regarding our financial results, we have disclosed (see below) adjusted EBITDA, a non-GAAP financial measure that we calculate as net income excluding share-based compensation expense (benefit), depreciation and amortization; income tax provision, interest income (expense), and other non-operational expenses. We have provided reconciliations below of net (loss) income to adjusted EBITDA, the most directly comparable GAAP financial measures.
We have included adjusted EBITDA, herein, because it is a key measure used by our management and Board of Directors to evaluate our operating performance, generate future operating plans, and make strategic decisions regarding the allocation of capital. In particular, the exclusion of certain expenses in calculating adjusted EBITDA facilitates operating performance comparability across reporting periods by removing the effect of non-cash expenses and other expenses. Accordingly, we believe that adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and Board of Directors.
We believe it is useful to exclude non-cash charges, such as share-based compensation expense (benefit) and depreciation and amortization from our adjusted EBITDA because the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations. We believe it is useful to exclude income tax provision and interest income (expense), as neither are components of our core business operations. We also believe that it is useful to exclude other non-operational expenses, employee severance, impairment of goodwill and intangible assets, and interest expense relating to an estimated unremitted prior sales tax accrual as these items are not indicative of our ongoing operations. Adjusted EBITDA has limitations as a financial measure, and these non-GAAP measures should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:
- Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future and adjusted EBITDA does not reflect capital expenditure requirements for such replacements or for new capital expenditures;
- Adjusted EBITDA does not reflect net share-based compensation. Share-based compensation has been, and will continue to be for the foreseeable future, a material recurring expense in our business and an important part of our compensation strategy;
- Adjusted EBITDA does not reflect interest income (expense), net; or changes in, or cash requirements for, our working capital;
- Adjusted EBITDA does not reflect transaction related costs and other items which are either not representative of our underlying operations or are incremental costs that result from an actual or planned transaction and include litigation matters, integration consulting fees, internal salaries and wages (to the extent the individuals are assigned full-time to integration and transformation activities) and certain costs related to integrating and converging IT systems;
- Adjusted EBITDA does not reflect certain non-operating expenses including the employee severance which reduces cash available to us;
- Adjusted EBITDA does not reflect certain non-operating expenses (income) including sales tax expense (income) relating to recording a liability for sales tax we did not collect from our customers;
- Other companies, including companies in our industry, may calculate adjusted EBITDA differently, which reduces the measures usefulness as comparative measures.
Because of these and other limitations, Adjusted EBITDA should only be considered as supplemental to, and alongside with other GAAP based financial performance measures, including various cash flow metrics, net income, net margin, and our other GAAP results.
The following table presents a reconciliation of net loss, the most directly comparable GAAP measure to Adjusted EBITDA for each of the periods indicated:
| Reconciliation of Unaudited Non-GAAP Measures PetMed Express, Inc. | ||||||||||||||||
| Three Months Ended | ||||||||||||||||
| ($ in thousands, except percentages) | June 30, 2026 | June 30, 2025 | $ Change | % Change | ||||||||||||
| Consolidated Reconciliation of GAAP Net Loss to Adjusted EBITDA: | ||||||||||||||||
| Net loss | $ | (6,145 | ) | $ | (34,152 | ) | $ | 28,007 | 82 | % | ||||||
| Add (subtract): | ||||||||||||||||
| Stock-based Compensation | 198 | 591 | (393 | ) | (66 | ) | % | |||||||||
| Income Taxes | 13 | 9 | 4 | 44 | % | |||||||||||
| Depreciation and Amortization | 2,148 | 2,283 | (135 | ) | (6 | ) | % | |||||||||
| Interest Expense (Income), Net | 338 | 198 | 140 | 71 | % | |||||||||||
| Employee Severance | — | 95 | (95 | ) | n/m | |||||||||||
| Professional Fees (1) | — | 1,021 | (1,021 | ) | n/m | |||||||||||
| Impairment of goodwill and intangible assets | — | 27,258 | (27,258 | ) | n/m | |||||||||||
| Adjusted EBITDA | $ | (3,448 | ) | $ | (2,697 | ) | $ | (751 | ) | 28 | % | |||||
(1) Consists of professional fees related to the investigation as previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2025. | ||||||||||||||||
________________________________________
1 Adjusted EBITDA is a non-GAAP financial measure. See “Non-GAAP Financial Measures” for additional information on non-GAAP financial measures and a reconciliation to the most comparable GAAP measures.
